Sign In
Buy GLMD
$0.621
+0.0220 (+3.67%)
At Close: Jul 31, 2026
– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine, a
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
04:10pm, Wednesday, 02'nd Apr 2025
TEL AVIV, Israel , April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic di
TEL AVIV, Israel , March 20, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
08:00am, Wednesday, 25'th Sep 2024
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measureme
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
07:00am, Thursday, 19'th Sep 2024
Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and
Galmed Pharma Surges 400%: What's Behind the Explosion?
02:41pm, Tuesday, 17'th Sep 2024
Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
06:30am, Wednesday, 10'th Apr 2024
Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
05:06pm, Thursday, 04'th Apr 2024
TEL AVIV, Israel , April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di
TEL AVIV, Israel , March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic d
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
04:32pm, Monday, 20'th Nov 2023
TEL AVIV, Israel , Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
08:30am, Tuesday, 26'th Sep 2023
TEL AVIV, Israel , Sept. 26, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
04:05pm, Friday, 22'nd Sep 2023
TEL AVIV, Israel , Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
09:30am, Friday, 14'th Jul 2023
TEL AVIV, Israel , July 14, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
09:26am, Thursday, 13'th Jul 2023
Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stoc
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
08:00am, Monday, 10'th Jul 2023
OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel , July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
